Here are three things to know.
- Mydayis is intended to treat ADHD symptoms in patients thirteen years or older.
- The once-daily drug features the same active ingredients as Shire’s popular ADHD drug Adderall, but is formulated to last up to 16 hours, according to Reuters.
- Shire plans to launch Mydayis in the third quarter of this year.
More articles on supply chain:
Global drug sales forecast falls for 1st time in decade
Stryker to acquire imaging technology company for $701M
SCOTUS decision reduces drugmakers’ product liability
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
